Corrective and Preventive Actions, Completion of an Audit, Audit Certificate
8 Corrective and Preventive Actions
Implementation of a CAPA plan after the conduct of an audit is necessary to eliminate present and potential causes of non-conformity and prevent re-occurrence or future occurrence. Once the conduct of the audit is complete the auditor should be provided a CAPA plan to the auditee that will be utilized to remediate issues of non-compliance and potential non-compliance identified during the audit process. The CAPA plan should, at minimum, require the auditee to identify the root-cause of audit findings and describe whether corrective and/or preventive actions will be necessary to address the audit findings.
9 Completion of an Audit
Upon receipt of the preliminary responses to the CAPA from the auditee, the audit is completed. Follow-up should be performed depending on the significance of the audit findings. CAPA follow-up and subsequent effectiveness verification should be ensured by continued interaction between the auditor and auditee until mutual agreement has been met that the CAPA have been addressed.
10 Audit Certificate
The auditor (including the auditing department manager) should prepare an audit certificate at the request of the sponsor. The sponsor should attach the audit certificate to a clinical trial/study report of the targeted trial. The audit certificate should contain the following information: • Information that identifies the trial, such as the chemical name or identification code of the investigational drug, the trial title, and the protocol number. • The date of issuing the audit certificate. • The contents of the audit (e.g., subjects and date of the audit, and date of issuing the audit report). • The name(s), title and address of the auditor (s)(and the auditing department manager). • The name and workplace address of the auditee.
Clinical Research News
Upcoming Clinical Research Events
-
26 – 28 September 2023
Fierce Pharma
United States -
29 September – 01 October 2023
SOCRA (Society of Clinical Research Associates) -
Canada -
08 – 11 October 2023
TransCelerate BioPharma
United States -
08 – 11 October 2023
SCDM (Society of Clinical Data Management)
United States -
16 – 17 October 2023
The Conference Forum
United States -
17 – 18 October 2023
Cambridge Innovation Institute
Spain -
01 – 03 November 2023
RQA (Research Quality Association)
United Kingdom -
11 – 15 November 2023
AMIA (American Medical Informatics Association)
United States -
15 – 16 November 2023
World BI
United States -
29 – 30 November 2023
Informa
Spain
Upcoming Clinical Trials
-
NCT06050070Not yet recruiting
-
NCT06049199Not yet recruitingListening Effort
-
NCT06050811Not yet recruiting
-
NCT06049576RecruitingClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma
-
NCT06050434Not yet recruiting
-
NCT06050057RecruitingCushing Syndrome | Pheochromocytoma | Adrenocortical Carcinoma | Adrenal Cortex Diseases | Adrenocortical Adenoma | Adrenal Tumor | Adrenalectomy; Status | Adrenal Mass | Adrenal Hyperplasia | Adrenal Disease
-
NCT06051240Not yet recruitingCognitive Impairment | Brain Tumor | Cognitive Decline | Memory Impairment | Radiotherapy Side Effect | Radiotherapy; Complications | Late Effect of Radiation
-
NCT06050928Recruiting
-
NCT06049784Not yet recruitingObstetric Labor Complications | Obstetric Trauma
-
NCT06049498Not yet recruiting
-
NCT06049381Not yet recruitingRelapsed Non-Hodgkin Lymphoma
-
NCT06051435RecruitingPrimary Dysmenorrhea